Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-31

Study Completion Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this trial is to assess the efficacy and safety of loading doses versus standard dose of intravenous Bondronat in reducing pain in patients with lung cancer and bone metastatic disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)

NCT01211002

Non-small Cell Lung Cancer

UNKNOWN PHASE4

A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT05949606

Non-small Cell Lung Cancer

RECRUITING PHASE1/PHASE2

A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients

NCT01531790

Non-Small Cell Lung Cancer

COMPLETED PHASE1

High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

NCT02284490

Brain Metastases

UNKNOWN PHASE2

Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies

NCT05042908

Advanced Malignant Tumor

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with lung cancer and bone metastatic disease may experience moderate or severe bone pain. Some researches have reported that loading doses Bondronat (6mg Bondronat on three consecutive days) had great efficacy in reducing pain in patients with malignant bone disease without unacceptable toxicities. So,we designed this clinical trial to compare the efficacy and safety profiles between loading doses Bondronat and standard dose Bondronat.Enrolled patients will receive an intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day. The targeted sample size is 120 individuals. Primary outcome measures will be bone pain response ( ≥ 25% decrease in mean pain score with a maximum of 15% increase in mean analgesic consumption). Secondary outcome measures will be efficacy including ECOG Performance status, analgesic consumption, bone markers, and safety profiles including AE and laboratory parameters.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Intravenous infusion of either 6mg Bondronat on three consecutive days

Group Type EXPERIMENTAL

Ibandronate (Bondronat)

Intervention Type DRUG

Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.

B

Intravenous infusion of 6mg Bondronat on one day

Group Type ACTIVE_COMPARATOR

Ibandronate (Bondronat)

Intervention Type DRUG

Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ibandronate (Bondronat)

Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

no other names

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Age ≥ 18 years
* Histological or cytological evidence of lung cancer
* Presence of bone metastases documented on bone X-ray, bone ECT, CT scan or MRI scan
* Mean pain score ≥ 4 during 3-day baseline period on the WORSE pain scale of the VAS
* Patients must be on a stable dose of analgesics over the 3-day baseline period (maximum 15% variation is allowed)
* ECOG Performance status of 0-3 (patients with PS of 3 must have their score based on bone pain, not underlying neoplastic disease)
* Adequate renal function: creatinine clearance ≥ 50 ml/min (cockroft formula) and serum creatinine ≤ 2.0mg/dl (168 µmol/L); ALT or AST within 2 times the upper limit of the normal range

Exclusion Criteria

* Patients with an uncontrolled infection
* Hypocalcemia
* Patients who have received a bisphosphonate within 3 weeks of the start of the Baseline period or who are currently receiving another bisphosphonate
* Patients with known hypersensitivity to any of the components of ibandronic acid
* Patients who are pregnant or lactating
* Radiotherapy to bone within the 28 days prior inclusion or during the trial duration
* Patient who are currently treated with any other investigational therapy or have received it within 30 days of the first schedule day of dosing

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No